Рекомендации EULAR по лечению системной красной волчанки

1. <div><p>Jonsson Н., Nived О., Sturfelt G. et al. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br. J. Rheumatol., 1990, 29, 185-188.</p><p>Boumpas D. Т., Austin H. A. 3rd, Fessler B. J. et al. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann. Intern. Med., 1995, 122, 940-950.</p><p>Boumpas D. Т., Fessler B. J., Austin H. A. 3rd et al. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann. Intern. Med., 1995, 123, 42-53.</p><p>Мок С. C., Lee K. W., Но С. Т., et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford), 2000, 39, 399-406.</p><p>Mikdashi J., Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology(Oxford), 2004, 43, 1555-1560.</p><p>Font J., Cervera R., Ramos-Casals M. et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin. Arthritis Rheum., 2004, 33, 217-230.</p><p>Alarcon G. S., McGwin G. Jr., Bastian H. M. Bastian et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis. Rheum., 2001, 45, 191-202.</p><p>Cervera R., Khamashta M. A., FontJ. etal. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore), 2003, 82, 299-308.</p><p>Manger K., Manger B., Repp R. et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338patients with systemic lupus erythematosus. Ann. Rheum. Dis., 2002, 61, 1065-1070.</p><p>Austin H. A. 3rd, Boumpas D. Т., Vaughan E. M. et al. et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney. Int., 1994, 45, 544-550.</p><p>Alarcon G. S., McGwin G. Jr., Bartolucci A. A. Bartolucci et al. et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum., 2001, 44, 2797-2806.</p><p>Petri M. Hopkins Lupus Cohort. 1999 update. Rheum. Dis. Clin. North. Am., 2000, 26, 199-213.</p><p>Cook R. J., Gladman D. D., Pericak D. et al. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J. Rheumatol., 2000, 27, 1892-1895.</p><p>Urowitz М. B., Gladman D. D. Measures of disease activity and damage in SLE. Baillieres Clin. Rheumatol., 1998, 12, 405-413.</p><p>Strand V. Clinical trial design in systemic lupus erythematosus: lessons learned and future directions. Lupus, 2004, 13, 406-411.</p><p>Stoll Т., Sutcliffe N., Mach J. et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology (Oxford), 2004, 43, 1039-1044.</p><p>Zecevic R. D., Vojvodic D., Ristic B. et al. Skin lesions-an indicator of disease activity in systemic lupus erythematosus?Lupus, 2001, 10, 364-367.</p><p>Mirzayan M. J., Schmidt R. E., Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford), 2000, 39, 1316-1319.</p><p>Ziakas P. D., Giannouli S., Zintzaras E. et al. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann. Rheum. Dis., 2005, 64, 13661369.</p><p>Ho A., Barr S. G., Magder L. S. et al. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum., 2001, 44, 23502357.</p><p>Illei G. G., Takada K, Parkin D. et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum., 2002, 46, 995-1002.</p><p>SwaakA. J., Groenwold J., Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann. Rheum. Dis., 1986, 45, 359-366.</p><p>Bootsma H., SpronkP., Derksen R. etal. Prevention of relapses in systemic lupus erythematosus. Lancet, 1995, 345, 1595-1599.</p><p>Abu-Shakra М., Urowitz М. B., Gladman D. D. et al. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J. Rheumatol., 1995, 22, 1265-1270.</p><p>Мок С. C., MakA., Chu W. P. etal. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore), 2005, 84, 218-224.</p><p>Bruce I. N., Urowitz М. B., Gladman D. D. et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum., 2003, 48, 31593167.</p><p>Asanuma Y., OeserA., ShintaniA. K. etal. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med., 2003, 349, 24072415.</p><p>Jimenez S., Garcia-Criado M. A., Tassies D. et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford), 2005, 44, 756-761.</p><p>BjornadalL., Yin L., Granath F. etal. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J. Rheumatol., 2004, 31, 713-719.</p><p>Gilboe I. М., Kvien Т. K, Haugeberg G. et al. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann. Rheum. Dis., 2000, 59,110-115.</p><p>Gladman D. D., Urowitz М. B., Chaudhry-Ahluwalia V. et al. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J. Rheumatol., 2001, 28, 761-765.</p><p>Bernatsky S., Boivin J. F., Joseph L. et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum., 2005, 52, 1481-1490.</p><p>Stege H., Budde M. A., Grether-Beck S. et al. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photodermatol. Photoimmunol. Photomed., 2000, 16, 256-259.</p><p>MiyakisS., LockshinM.,Atsumi T. et al. International consesus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemostasis., 2006, 4, 295-306.</p><p>Sambrook P., Birmingham J., Kelly P. et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N. Engl. J. Med., 1993, 328, 1747-1752.</p><p>Petri М., Kim M. Y., Kalunian К С. etal. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med., 2005, 353, 25502558.</p><p>Bhattoa H. P., Bettembuk P., Balogh A. et al. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Osteoporos. Int., 2004, 15, 396-404.</p><p>Mitsikostas D. D., Sfikakis P. P., Goadsby P. J. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain, 2004, 127, 1200-1209.</p><p>Carlomagno S., Migliaresi S., Ambrosone L. et al. Cognitive impairment in systemic lupus erythematosus: a follow-up study. J. Neurol., 2000, 247, 273279. "</p><p>Мок С. C., Lau C. S., Chan E. Y. et al. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J. Rheumatol., 1998, 25, 467-473.</p><p>Balasch J., Creus М., Fabregues F. et al. Antiphospholipid antibodies and human reproductive failure. Hum. Reprod., 1996, 11, 2310-2315.</p><p>Hayslett J. P. Fhe effect of systemic lupus erythematosus on pregnancy and pregnancy outcome. Am. J. Reprod. Immunol., 1992, 28, 199-204.</p><p>Nossent H. C., Swaak F. J. Systemic lupus erythematosus. VI. Analysis of the interrelationship with pregnancy. J. Rheumatol., 1990, 17, 771-776.</p><p>Carmona F., Font J., Azulay M. et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am. J. Reprod. Immunol., 2001, 46, 274-279.</p><p>Moroni G., Ponticelli C. Fhe risk of pregnancy in patients with lupus nephritis. J. Nephrol., 2003, 16, 161-167.</p><p>Hardy C. J., Palmer B. P., Morton S. J. et al. Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study. Rheumatology (Oxford), 1999, 38, 559-563.</p><p>LockwoodC. J., Romero R., FeinbergR. F. etal. Fhe prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am. J. Obstet. Gynecol., 1989, 161, 369-373.</p><p>Buyon J. P., Hiebert R, Copel J. et al. Autoimmune- associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J. Am. Coll. Cardiol., 1998, 31, 1658-1666.</p><p>Levy R. A., Vilela V. S., Cataldo M. J. et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus, 2001, 10, 401-404.</p><p>Khamashta M. A., Cuadrado M. J., Mujic F. et al. Fhe management of thrombosis in the antiphospho- lipid-antibody syndrome. N. Engl. J. Med., 1995, 332, 993-997.</p><p>Empson М., Lassere М., Craig J. et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst. Rev., 2005, CD002859.</p><p>Baldwin D. S., Gluck М. C., Lowenstein J. et al. Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am. J. Med., 1977, 62, 12-30.</p><p>Flanc R. S., Roberts M. A., Strippoli G. F. et al. Freatment for lupus nephritis. Cochrane Database Syst. Rev., 2004, CD002922.</p><p>Austin H. A. 3rd, Klippel J. H., Balow J. E. et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med., 1986, 314, 614-619.</p><p>Chan Т. М., Li F. K, Fang C. S. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med., 2000, 343, 1156-1162.</p><p>Illei G. G., Austin H. A., Crane M. et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long- term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med., 2001, 135 248-257.</p><p>Liang М. H., Schur P. H., Fortin P. J. et al. Fhe American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum., 2006, 54, 421-432.</p><p>Van Vollenhoven R., Gunnarsson I. In lupus nephritis, the benefit ofrituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al. Arthritis Rheum., 2005, 52, 40504051 [author reply 1-2].</p><p>Ioannidis J. P., Boki K. A., Katsorida М. E. et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int., 2000, 57, 258-264.</p></div><br />